Vanguard Capital Management
MRVI icon

Vanguard Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Vanguard Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33M Sell
5,283,665
-166,037
-3% -$717K ﹤0.01% 2155
2026
Q1 		$15.4M Buy
+5,449,702
New +$18.5M ﹤0.01% 2490

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's MRVI Position: Q2 2026 in Review

Vanguard Capital Management reduced its Maravai LifeSciences (MRVI) stake by 3% in Q2 2026, selling an estimated $717K and leaving 5,283,665 shares worth $33M. The position accounts for ﹤0.01% of the portfolio, ranked #2155.

Vanguard Capital Management first reported a position in MRVI in Q1 2026 and has held it in 2 quarters since. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Vanguard Capital Management held 5,283,665 shares of Maravai LifeSciences worth $33M as of Q2 2026.
  • Vanguard Capital Management sold 166,037 Maravai LifeSciences shares in Q2 2026, an estimated $717K.
  • Maravai LifeSciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2155 holding.
  • Vanguard Capital Management first reported a position in Maravai LifeSciences in Q1 2026 and has held it in 2 quarters since.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.